Skip to main content
. Author manuscript; available in PMC: 2021 Mar 22.
Published in final edited form as: Cell Mol Life Sci. 2017 Oct 25;75(5):939–963. doi: 10.1007/s00018-017-2681-z

Fig. 10.

Fig. 10

CRT0066101 treatment diminishes the activity of PKD2 protein and its substrate c-Jun in xenograft bladder cancer tumor explants. Immunoblot analysis of PKD2, phospho-PKD2 (Ser706/710), phospho-PKD2 (Ser876), phospho-PKD2 (Ser916), c-Jun, and phospho-c-Jun (Ser63) in cellular lysates from vehicle-treated (5% dextrose) and CRT0066101-treated UMUC1 tumor explants, as described in “Materials and methods”. A total of 60 or 80 μg cell extract protein was subjected to SDS-PAGE and immunoblotted with antibodies against the indicated proteins, or with a β-actin antibody to verify equal protein loading. The levels and activities of PKD2 protein in both vehicle-treated group and CRT0066101-treated group are shown in a, while the expression and activity of c-Jun protein in vehicle-treated and CRT0066101-treated groups are presented in b